ArticleSleep2016
Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study.
Article in Sleep, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06336057 (Mentalizating in Adults Suffering from Narcolepsy Type 1, a Comparative Prospective Study.), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mentalizating in Adults Suffering from Narcolepsy Type 1, a Comparative Prospective Study.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Diagnostic challenges and burden of idiopathic hypersomnia: a systematic literature review.Sleep advances : a journal of the Sleep Research Society · 2024Article
- The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I.Frontiers in immunology · 2023Article
- Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations.Nature and science of sleep · 2023Review
- Exploring Addictive Online Behaviors in Patients with Narcolepsy Type 1.Healthcare (Basel, Switzerland) · 2022Article
- Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Article
- Hypocretin/Orexin Interactions with Norepinephrine Contribute to the Opiate Withdrawal Syndrome.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- Pleasure, addiction, and hypocretin (orexin).Handbook of clinical neurology · 2021Review
- Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.Current treatment options in neurology · 2019Review
- The neurobiological basis of narcolepsy.Nature reviews. Neuroscience · 2019Review
- The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2018Review
- Rotating night shift work and adherence to unhealthy lifestyle in predicting risk of type 2 diabetes: results from two large US cohorts of female nurses.BMJ (Clinical research ed.) · 2018Article
- Narcolepsy and Psychiatric Disorders: Comorbidities or Shared Pathophysiology?Medical sciences (Basel, Switzerland) · 2018Review
- Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994.Addiction (Abingdon, England) · 2017Article
- Orexin/Hypocretin System: Role in Food and Drug Overconsumption.International review of neurobiology · 2017Review
- Management of Narcolepsy.Current treatment options in neurology · 2016Review
- Treatment Options for Narcolepsy.CNS drugs · 2016Review
- Narcolepsy and psychiatric comorbidity: a review of the literature.International journal of clinical and health psychology : IJCHPArticle
- Cannabis Use in Central Disorders of Hypersomnolence in the Netherlands.Medical cannabis and cannabinoidsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesBasic experiments support the impact of hypocretin on hyperarousal and motivated state required for increasing drug craving. Our aim was to assess the frequencies of smoking, alcohol and drug use, abuse and dependence in narcolepsy type 1 (NT1, hypocretin-deficient), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH) (non-hypocretin-deficient conditions), in comparison to controls. We hypothesized that NT1 patients would be less vulnerable to drug abuse and addiction compared to other hypersomniac patients and controls from general population.
methodsWe performed a cross-sectional study in French reference centres for rare hypersomnia diseases and included 450 adult patients (median age 35 years; 41.3% men) with NT1 (n = 243), NT2 (n = 116), IH (n = 91), and 710 adult controls. All participants were evaluated for alcohol consumption, smoking habits, and substance (alcohol and illicit drug) abuse and dependence diagnosis during the past year using the Mini International Neuropsychiatric Interview.
resultsAn increased proportion of both tobacco and heavy tobacco smokers was found in NT1 compared to controls and other hypersomniacs, despite adjustments for potential confounders. We reported an increased regular and frequent alcohol drinking habit in NT1 versus controls but not compared to other hypersomniacs in adjusted models. In contrast, heavy drinkers were significantly reduced in NT1 versus controls but not compared to other hypersomniacs. The proportion of patients with excessive drug use (codeine, cocaine, and cannabis), substance dependence, or abuse was low in all subgroups, without significant differences between either hypersomnia disorder categories or compared with controls.
conclusionsWe first described a low frequency of illicit drug use, dependence, or abuse in patients with central hypersomnia, whether Hcrt-deficient or not, and whether drug-free or medicated, in the same range as in controls. Conversely, heavy drinkers were rare in NT1 compared to controls but not to other hypersomniacs, without any change in alcohol dependence or abuse frequency. Although disruption of hypocretin signaling in rodents reduces drug-seeking behaviors, our results do not support that hypocretin deficiency constitutes a protective factor against the development of drug addiction in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.